Condition: Coronary Artery Disease · Sponsor: Samsung Medical Center
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
This description comes directly from the study's public registry record.
Ki Hong Choi, MD, PhD · 82-2-3410-3419 · cardiokh@gmail.com
Danbee Kang, PhD · 82-2-2148-7197 · dbee.kang@gmail.com
Always discuss trial participation with your own doctor first.
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07068490